APS news

Latest 2 stories · newest Jun 30, 2026

APS

Aptose Biosciences completes acquisition by Hanmi Pharmaceutical for C$2.41 per share.

Aptose Biosciences announced the closing of the acquisition by Hanmi Pharmaceutical, delisting shares on July 3. Shareholders received C$2.41 per share, representing a 28% premium over the prior 30-day VWAP.

M&A Jun 30, 2026 sentiment +0.90 SEC filing ↗

APS

Aptose-Hanmi deal closing delayed to June pending Korean regulatory approvals

Aptose Biosciences announced that closing of its previously announced Plan of Arrangement with Hanmi Pharmaceutical has been further delayed due to pending Korean regulatory approvals, now targeted for June. The company received an additional US$2.0 million advance from Hanmi under a US$11.9 million…

M&A May 29, 2026 sentiment -0.15 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same APS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/APS/newsSTART FREE